Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques

Lia Vassena, Huiyi Miao, Raffaello Cimbro, Mauro S. Malnati, Giulia Cassina, Michael A. Proschan, Vanessa M. Hirsch, Bernard A. Lafont, Michel Morre, Anthony S. Fauci, Paolo Lusso

Research output: Contribution to journalArticle

Abstract

Although treatment with interleukin-7 (IL-7) was shown to transiently expand the naïve and memory T-cell pools in patients with chronic HIV-1 infection receiving antiretroviral therapy (ART), it is uncertain whether a full immunologic reconstitution can be achieved. Moreover, the effects of IL-7 have never been evaluated during acute HIV-1 (or SIV) infection, a critical phase of the disease in which the most dramatic depletion of CD4+ T cells is believed to occur. In the present study, recombinant, fully glycosylated simian IL-7 (50 μg/kg, s.c., once weekly for 7 weeks) was administered to 6 rhesus macaques throughout the acute phase of infection with a pathogenic SIV strain (mac251); 6 animals were infected at the same time and served as untreated controls. Treatment with IL-7 did not cause clinically detectable side effects and, despite the absence of concomitant ART, did not induce significant increases in the levels of SIV replication except at the earliest time point tested (day 4 post-infection). Strikingly, animals treated with IL-7 were protected from the dramatic decline of circulating naïve and memory CD4+ T cells that occurred in untreated animals. Treatment with IL-7 induced only transient T-cell proliferation, but it was associated with sustained increase in the expression of the anti-apoptotic protein Bcl-2 on both CD4+ and CD8+ T cells, persistent expansion of all circulating CD8+ T-cell subsets, and development of earlier and stronger SIV Tat-specific T-cell responses. However, the beneficial effects of IL-7 were not sustained after treatment interruption. These data demonstrate that IL-7 administration is effective in protecting the CD4+ T-cell pool during the acute phase of SIV infection in macaques, providing a rationale for the clinical evaluation of this cytokine in patients with acute HIV-1 infection.

Original languageEnglish
Article numbere1002636
JournalPLoS Pathogens
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Interleukin-7
Macaca mulatta
T-Lymphocytes
Infection
HIV-1
Therapeutics
HIV Infections
Apoptosis Regulatory Proteins
Macaca
T-Lymphocyte Subsets
Cell Proliferation
Cytokines

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques. / Vassena, Lia; Miao, Huiyi; Cimbro, Raffaello; Malnati, Mauro S.; Cassina, Giulia; Proschan, Michael A.; Hirsch, Vanessa M.; Lafont, Bernard A.; Morre, Michel; Fauci, Anthony S.; Lusso, Paolo.

In: PLoS Pathogens, Vol. 8, No. 4, e1002636, 04.2012.

Research output: Contribution to journalArticle

Vassena, L, Miao, H, Cimbro, R, Malnati, MS, Cassina, G, Proschan, MA, Hirsch, VM, Lafont, BA, Morre, M, Fauci, AS & Lusso, P 2012, 'Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques', PLoS Pathogens, vol. 8, no. 4, e1002636. https://doi.org/10.1371/journal.ppat.1002636
Vassena, Lia ; Miao, Huiyi ; Cimbro, Raffaello ; Malnati, Mauro S. ; Cassina, Giulia ; Proschan, Michael A. ; Hirsch, Vanessa M. ; Lafont, Bernard A. ; Morre, Michel ; Fauci, Anthony S. ; Lusso, Paolo. / Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques. In: PLoS Pathogens. 2012 ; Vol. 8, No. 4.
@article{944d2ce20edd4f0baa1a79d0806d8ac9,
title = "Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques",
abstract = "Although treatment with interleukin-7 (IL-7) was shown to transiently expand the na{\"i}ve and memory T-cell pools in patients with chronic HIV-1 infection receiving antiretroviral therapy (ART), it is uncertain whether a full immunologic reconstitution can be achieved. Moreover, the effects of IL-7 have never been evaluated during acute HIV-1 (or SIV) infection, a critical phase of the disease in which the most dramatic depletion of CD4+ T cells is believed to occur. In the present study, recombinant, fully glycosylated simian IL-7 (50 μg/kg, s.c., once weekly for 7 weeks) was administered to 6 rhesus macaques throughout the acute phase of infection with a pathogenic SIV strain (mac251); 6 animals were infected at the same time and served as untreated controls. Treatment with IL-7 did not cause clinically detectable side effects and, despite the absence of concomitant ART, did not induce significant increases in the levels of SIV replication except at the earliest time point tested (day 4 post-infection). Strikingly, animals treated with IL-7 were protected from the dramatic decline of circulating na{\"i}ve and memory CD4+ T cells that occurred in untreated animals. Treatment with IL-7 induced only transient T-cell proliferation, but it was associated with sustained increase in the expression of the anti-apoptotic protein Bcl-2 on both CD4+ and CD8+ T cells, persistent expansion of all circulating CD8+ T-cell subsets, and development of earlier and stronger SIV Tat-specific T-cell responses. However, the beneficial effects of IL-7 were not sustained after treatment interruption. These data demonstrate that IL-7 administration is effective in protecting the CD4+ T-cell pool during the acute phase of SIV infection in macaques, providing a rationale for the clinical evaluation of this cytokine in patients with acute HIV-1 infection.",
author = "Lia Vassena and Huiyi Miao and Raffaello Cimbro and Malnati, {Mauro S.} and Giulia Cassina and Proschan, {Michael A.} and Hirsch, {Vanessa M.} and Lafont, {Bernard A.} and Michel Morre and Fauci, {Anthony S.} and Paolo Lusso",
year = "2012",
month = "4",
doi = "10.1371/journal.ppat.1002636",
language = "English",
volume = "8",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques

AU - Vassena, Lia

AU - Miao, Huiyi

AU - Cimbro, Raffaello

AU - Malnati, Mauro S.

AU - Cassina, Giulia

AU - Proschan, Michael A.

AU - Hirsch, Vanessa M.

AU - Lafont, Bernard A.

AU - Morre, Michel

AU - Fauci, Anthony S.

AU - Lusso, Paolo

PY - 2012/4

Y1 - 2012/4

N2 - Although treatment with interleukin-7 (IL-7) was shown to transiently expand the naïve and memory T-cell pools in patients with chronic HIV-1 infection receiving antiretroviral therapy (ART), it is uncertain whether a full immunologic reconstitution can be achieved. Moreover, the effects of IL-7 have never been evaluated during acute HIV-1 (or SIV) infection, a critical phase of the disease in which the most dramatic depletion of CD4+ T cells is believed to occur. In the present study, recombinant, fully glycosylated simian IL-7 (50 μg/kg, s.c., once weekly for 7 weeks) was administered to 6 rhesus macaques throughout the acute phase of infection with a pathogenic SIV strain (mac251); 6 animals were infected at the same time and served as untreated controls. Treatment with IL-7 did not cause clinically detectable side effects and, despite the absence of concomitant ART, did not induce significant increases in the levels of SIV replication except at the earliest time point tested (day 4 post-infection). Strikingly, animals treated with IL-7 were protected from the dramatic decline of circulating naïve and memory CD4+ T cells that occurred in untreated animals. Treatment with IL-7 induced only transient T-cell proliferation, but it was associated with sustained increase in the expression of the anti-apoptotic protein Bcl-2 on both CD4+ and CD8+ T cells, persistent expansion of all circulating CD8+ T-cell subsets, and development of earlier and stronger SIV Tat-specific T-cell responses. However, the beneficial effects of IL-7 were not sustained after treatment interruption. These data demonstrate that IL-7 administration is effective in protecting the CD4+ T-cell pool during the acute phase of SIV infection in macaques, providing a rationale for the clinical evaluation of this cytokine in patients with acute HIV-1 infection.

AB - Although treatment with interleukin-7 (IL-7) was shown to transiently expand the naïve and memory T-cell pools in patients with chronic HIV-1 infection receiving antiretroviral therapy (ART), it is uncertain whether a full immunologic reconstitution can be achieved. Moreover, the effects of IL-7 have never been evaluated during acute HIV-1 (or SIV) infection, a critical phase of the disease in which the most dramatic depletion of CD4+ T cells is believed to occur. In the present study, recombinant, fully glycosylated simian IL-7 (50 μg/kg, s.c., once weekly for 7 weeks) was administered to 6 rhesus macaques throughout the acute phase of infection with a pathogenic SIV strain (mac251); 6 animals were infected at the same time and served as untreated controls. Treatment with IL-7 did not cause clinically detectable side effects and, despite the absence of concomitant ART, did not induce significant increases in the levels of SIV replication except at the earliest time point tested (day 4 post-infection). Strikingly, animals treated with IL-7 were protected from the dramatic decline of circulating naïve and memory CD4+ T cells that occurred in untreated animals. Treatment with IL-7 induced only transient T-cell proliferation, but it was associated with sustained increase in the expression of the anti-apoptotic protein Bcl-2 on both CD4+ and CD8+ T cells, persistent expansion of all circulating CD8+ T-cell subsets, and development of earlier and stronger SIV Tat-specific T-cell responses. However, the beneficial effects of IL-7 were not sustained after treatment interruption. These data demonstrate that IL-7 administration is effective in protecting the CD4+ T-cell pool during the acute phase of SIV infection in macaques, providing a rationale for the clinical evaluation of this cytokine in patients with acute HIV-1 infection.

UR - http://www.scopus.com/inward/record.url?scp=84861208977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861208977&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.1002636

DO - 10.1371/journal.ppat.1002636

M3 - Article

C2 - 22511868

AN - SCOPUS:84861208977

VL - 8

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 4

M1 - e1002636

ER -